According to the recent guidelines of the American Diabetes Association, nephroprotective effects were reported for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) and three GLP-1 receptor agonists (liraglutide, semaglutide and dulaglutide) [16]. The gene discussed is GLP1R; the disease is diabetes mellitus.